infigratinib phosphate

Drug Overview

Infigratinib phosphate is a highly specialized cancer medication. It falls under the category of a “Smart Drug” or a “Targeted Therapy.” Unlike traditional chemotherapy, which attacks all fast-growing cells in the body, this medication is designed to seek out and block specific signals that certain cancer cells use to grow and spread.

• Generic Name: infigratinib phosphate
• US Brand Names: Truseltiq
• Drug Class: Kinase Inhibitor / Targeted Therapy (Selective FGFR Inhibitor)
• Route of Administration: Oral (Capsule)
• FDA Approval Status: Infigratinib received “accelerated approval” from the US Food and Drug Administration (FDA) in May 2021 for specific bile duct cancers. However, in May 2024, the manufacturer voluntarily withdrew the drug from the US market. This withdrawal was not due to safety issues. Instead, the company could not enroll enough patients in a required Phase 3 clinical trial to confirm the drug’s long-term benefits. Despite this, it remains an important drug in ongoing global clinical research.
  
  Read about the targeted therapy uses of infigratinib phosphate. Our expert oncologists provide tailored care plans using recent research.

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Targeted Therapy works, it is helpful to look at the biology of a cancer cell.

Normally, cells in the human body have “antennas” on their surface. These antennas receive signals from the body telling the cell when to divide, grow, or die. One family of these antennas is called Fibroblast Growth Factor Receptors (FGFRs). In healthy bodies, FGFRs help with wound healing, creating new blood vessels, and tissue repair.

However, in certain cancers, the DNA inside the cell becomes damaged. The genes that build the FGFR antennas can mutate or fuse with other genes. When this happens, the FGFR antennas get stuck in the “ON” position. They constantly tell the cancer cells to multiply rapidly and build new blood vessels to feed the tumor.

Here is how infigratinib works at the molecular level to stop this:

• Entering the System: Once the patient swallows the capsule, the drug enters the bloodstream and travels to the tumor sites.
• Targeting the Receptor: Infigratinib is specifically designed to fit perfectly into the chemical engine (the ATP-binding pocket) of the abnormal FGFR antennas (specifically FGFR1, FGFR2, and FGFR3).
• Blocking the Signal: By locking into this pocket, the drug cuts off the power supply to the antenna.
• Cell Death: Because the cancer cell relies entirely on this “ON” signal to survive, blocking the signal stops the cell from dividing. Without this growth signal, the cancer cell eventually dies, a process known as apoptosis.

FDA-Approved Clinical Indications

Because the marketing status of the drug was voluntarily discontinued in the US in 2024, it is currently accessed primarily through clinical trials or specialized compassionate use programs.

• Oncological Uses (Cancer Care):
  • Cholangiocarcinoma: It was previously approved for adults with previously treated, locally advanced, or metastatic cholangiocarcinoma (bile duct cancer) that has a specific genetic change called an FGFR2 fusion or rearrangement.
  • Urothelial Carcinoma: It is currently being studied in clinical trials for advanced bladder cancers that have FGFR3 gene mutations.
  • Solid Tumors and Brain Cancer: Ongoing clinical trials are testing it for glioblastoma (a type of brain cancer) and other advanced solid tumors driven by FGFR mutations.
• Non-oncological Uses:
  • Achondroplasia: Interestingly, FGFR3 also regulates bone growth. Infigratinib is currently in Phase 3 clinical trials (as of 2025) to treat children with achondroplasia, the most common form of short-limbed dwarfism. At much lower doses, the drug helps correct bone growth pathways.

Dosage and Administration Protocols

Because infigratinib is a powerful kinase inhibitor, it must be taken strictly according to a doctor’s schedule. The medication is taken in 28-day cycles to allow the body time to rest.

Dose Adjustments for Organ Insufficiency

If a patient has underlying kidney or liver issues, the body cannot clear the drug as efficiently, leading to a buildup of the medication. Doctors will adjust the dose as follows:

• Mild to Moderate Renal (Kidney) Impairment: Reduce dose to 100 mg once daily.
• Mild Hepatic (Liver) Impairment: Reduce dose to 100 mg once daily.
• Moderate Hepatic (Liver) Impairment: Reduce dose to 75 mg once daily.

Clinical Efficacy and Research Results

• Clinical studies (2020–2025) show that infigratinib benefits patients with specific genetic mutations after chemotherapy failure. In Phase 2 trial CBGJ398X2204 (108 advanced bile duct cancer patients): ORR 23.1%, DoR 5.0 months, PFS 7.3 months, OS 12.2 months, significant given historical 5-year survival of ~2%.

More recently, research published in late 2025 has demonstrated the drug’s effectiveness in laboratory settings when combined with other targeted drugs (like ibrutinib) for treating aggressive B-cell lymphomas.

Safety Profile and Side Effects

Like all medications, infigratinib can cause side effects. Because it blocks FGFRs, which are also found in healthy tissues like the eyes, mouth, and kidneys, the side effects are different from traditional chemotherapy.

Important Warnings

While there is no formal “Black Box Warning,” there are major clinical warnings regarding two specific issues: Hyperphosphatemia (high phosphorus levels in the blood) and Retinal Pigment Epithelial Detachment (fluid buildup in the eye).

Common Side Effects (>10%)

• Hyperphosphatemia: Affecting up to 77% of patients. FGFRs normally help the kidneys control phosphorus. When blocked, phosphorus builds up in the blood.
• Eye Disorders: Affecting up to 67% of patients, presenting as dry eyes, blurry vision, or floating spots.
• Stomatitis: Mouth sores and inflammation occur in roughly 54% of patients.
• Fatigue: Extreme tiredness was reported by about 40% of patients.
• Hyponatremia: Low sodium levels in the blood.

Serious Adverse Events

• Retinal Pigment Epithelial Detachment (RPED): A severe condition where fluid builds up under the retina in the back of the eye, which can lead to vision loss if not treated.
• Soft Tissue Mineralization: If blood phosphorus levels stay too high for too long, calcium-phosphorus crystals can form in the blood vessels and organs, causing severe organ damage.
• Embryo-Fetal Toxicity: The drug can cause severe birth defects or loss of pregnancy.

Management Strategies

• For High Phosphorus: Doctors will strictly monitor blood tests. If levels rise, patients are prescribed “phosphate binders” (like sevelamer) to take with meals, which block phosphorus from being absorbed from food.
• For Eye Issues: Patients must see an eye doctor (ophthalmologist) before starting treatment, at 1 month, 3 months, and every 3 months afterward. If RPED occurs, the drug must be paused immediately.

Connection to Stem Cell and Regenerative Medicine

While infigratinib is primarily a cancer-fighting agent, recent studies published in 2025 have explored its role in modulating the immune system and tumor microenvironments. In studies involving B-cell lymphomas (Mantle Cell and Marginal Zone Lymphoma), researchers discovered that combining infigratinib with targeted immunotherapies or PI3K inhibitors successfully reversed drug resistance. Furthermore, its ability to influence bone growth pathways (as seen in pediatric achondroplasia trials) touches upon principles of developmental and regenerative medicine, showcasing how kinase inhibitors can physically alter and normalize bone tissue development.

Patient Management and Practical Recommendations

Patient safety requires strict monitoring and cooperation between the patient, their oncologist, and their pharmacy team.

Pre-treatment Tests to be Performed

1. Genetic Testing: An FDA-approved biomarker test (like FoundationOne CDx) must be done on the tumor tissue to confirm the presence of an FGFR2 fusion. The drug will not work without this mutation.
2. Ophthalmology Exam: A full eye exam, including a scan of the retina called an OCT (Optical Coherence Tomography), must be completed to establish a baseline.
3. Comprehensive Blood Panel: To check baseline phosphorus, calcium, kidney function, and liver function.
4. Pregnancy Test: Required for women of childbearing age before starting therapy.

Precautions During Treatment

• Birth Control: Both men and women must use highly effective contraception during treatment and for at least one month after the final dose.
• Dietary Restrictions: Patients must adopt a low-phosphate diet, avoiding processed foods, dark colas, and excessive dairy.

“Do’s and Don’ts” List

• DO take the medication on an empty stomach at the same time every day.
• DO swallow the capsules whole with a large glass of water.
• DO use artificial tears or hydrating eye drops if your eyes feel dry.
• DON’T crush, chew, open, or dissolve the capsules.
• DON’T eat grapefruit, pomelos, pomegranates, or drink their juices, as these fruits interfere with how the liver processes the drug.
• DON’T take over-the-counter vitamins or supplements containing phosphorus or calcium without your doctor’s explicit approval.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Infigratinib is a complex medical treatment that requires close supervision by a qualified oncologist. Always consult with a healthcare professional regarding diagnosis, treatment options, potential side effects, and eligibility for ongoing clinical trials. This guide should not replace the official prescribing information or direct advice from your medical team.